RNA in Cancer Immunotherapy: Unlocking the Potential of the Immune System
Open Access
- 18 May 2022
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 28 (18), 3929-3939
- https://doi.org/10.1158/1078-0432.ccr-21-3304
Abstract
Recent advances in the manufacturing, modification, purification, and cellular delivery of ribonucleic acid (RNA) have enabled the development of RNA-based therapeutics for a broad array of applications. The approval of two SARS-CoV-2–targeting mRNA-based vaccines has highlighted the advances of this technology. Offering rapid and straightforward manufacturing, clinical safety, and versatility, this paves the way for RNA therapeutics to expand into cancer immunotherapy. Together with ongoing trials on RNA cancer vaccination and cellular therapy, RNA therapeutics could be introduced into clinical practice, possibly stewarding future personalized approaches. In the present review, we discuss recent advances in RNA-based immuno-oncology together with an update on ongoing clinical applications and their current challenges.Keywords
Funding Information
- Belgian Foundation (FAF-C/2018/1222 (2018-128), FAF-F/2018/1223 (2018-089))
- VLAIO (HBC.2019.2522, HBC.2019.2564)
This publication has 134 references indexed in Scilit:
- Dendritic Cells Loaded With mRNA Encoding Full-length Tumor Antigens Prime CD4+ and CD8+ T Cells in Melanoma PatientsMolecular Therapy, 2012
- Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNANucleic Acids Research, 2011
- Therapeutic Vaccination With an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Advanced MelanomaJournal of Immunotherapy, 2011
- RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic PlatformAnnual Review of Pharmacology and Toxicology, 2010
- Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological StabilityMolecular Therapy, 2008
- Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+ regulatory T cellsJournal of Leukocyte Biology, 2007
- CD83 expression on dendritic cells and T cells: Correlation with effective immune responsesEuropean Journal of Immunology, 2007
- Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cellsBlood, 2006
- Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNAImmunity, 2005
- Revealing the world of RNA interferenceNature, 2004